Abstract Pneumocystis jirovecii is an opportunistic pathogen responsible for severe pneumonia in immunocompromised patients. Its diagnosis has been based upon direct microscopy either by classic staining (Gomori Grocott) or by epifluorescence microscopy (immunofluorescence staining, IFS), both of which are time-consuming and low on sensitivity. Our aim was to develop a flow cytometric (FC) protocol for the detection of P. jirovecii on respiratory samples. In our study, 420 respiratory samples were analysed in parallel by IFS and FC, and compared from clinical diagnosis to its resolution upon specific anti-Pneumocystis therapy. The optimum specific antibody concentration for FC analysis was determined to be 10 µg/ml, without any crossreactions to bacteria or fungi. All positive cases detected by IFS were positive by FC; however, FC classified eight samples to be positive which were classified as negative by routine technique. These samples were obtained from patients with respiratory symptoms who responded favourably to Pneumocystis-specific therapy and were subsequently considered to be true-positives. Using clinical diagnosis as a reference method, FC showed 100% sensitivity and specificity, whereas IFS showed 90.9% sensitivity and 100% specificity. According to our results, a new diagnostic approach is now available to detect P. jirovecii in respiratory samples.
Introduction
Pneumocystis jirovecii (previously named Pneumocystis carinii) is an atypical fungus. For 80 years, it was considered to be a protozoan, since its diagnostic form is a cyst, but ribosomal RNA and DNA studies demonstrated similarities to fungus [1] . In 2001, this microorganism was officially reclassified as a fungus belonging to the class Archiascomycetes [1] and was renamed P. jirovecii [2] . In humans, this pathogen is responsible for an opportunistic infection at the lower respiratory tract, but it can lead to severe Pneumocystis pneumonia (PcP) in immunocompromised patients, particularly in those with AIDS [3, 4] . Prior to the AIDS epidemic, P. jirovecii had been sporadically reported as a cause of death in malnourished infants and responsible for epidemics in institutions like nursing homes and hospitals [5] . Currently, it represents the most frequent AIDS opportunistic pathogen, although PcP incidence has decreased significantly due to the extensive use of highly active anti-retroviral therapy (HAART) and prophylactic treatment [4] [5] [6] . PcP may also represent a small fraction of respiratory infections in patients with pulmonary diseases such as chronic obstructive pulmonary disease (COPD) or displaying immunity conditions like malignancy [7, 8] .
Over the past 15 years, P. jirovecii carriage in healthy subjects has been widely demonstrated through the presence of anti-P. jirovecii antibodies in their serum, with serologic analysis being used simply for the assessment of the infection epidemiology [9] . PcP, however, is considered to result from de novo infection rather than from the reactivation of a latent infection [6] . It is assumed that human transmission of P. jirovecii occurs through the airborne route, as suggested by studies performed in rodent models [6] . Nonetheless, inter-individual transmission has been suggested due to the occurrence of PcP case clusters in hospitals, namely, in paediatrics, hematology-oncology, intensive care, transplantation unit and infectious diseases units [10] . P. jirovecii may be exhaled to the environment from infected patients, as demonstrated from cyst DNA detection in air filters from the hospital rooms of patients who developed PcP [10] .
The detection of P. jirovecii in an infected patient is based upon the direct visualisation of organisms (cysts, sporocysts or trophozoites) in clinical specimens, such as bronchoalveolar lavage (BAL), induced sputum (IS) or lung biopsy, which is the gold-standard specimen [6, 11] . Although specific fluorescent staining techniques were developed for assessment under fluorescent microscopy, such methods are very time-consuming, too cumbersome and subject to human error, especially when samples yield a low number of P. jirovecii organisms [11] . Molecular studies such as polymerase chain reaction (PCR) presented a higher sensitivity and variable specificity when compared to the microscopic detection of P. jirovecii in BAL [12, 13] . However, PCR remains unavailable in most clinical microbiology laboratories and is an expensive technique [14, 15] . More so, a variable specificity has been described ranging from 62.5 to 100%, depending on the type of specimen [14, 15] . Distinct applications of flow cytometry (FC) in microbiology have been developed by our group in order to increase the diagnostic sensitivity in clinical samples [16] [17] [18] . In the present study, we have developed and optimised a specific FC protocol for the detection of P. jirovecii on respiratory samples.
Materials and methods

Clinical specimens
A total of 420 samples, including 380 BAL and bronchial washing (BW) specimens, and 40 bronchial secretion (BS) aspirates, were prospectively collected from patients with different immunological conditions. From those 420 patients, 130 were HIV-positive. Samples were kindly provided by the Microbiology Laboratories of several Portuguese hospitals, namely, Hospital São João (HSJ, Porto, Portugal), Instituto Português de Oncologia Francisco Gentil (IPOFG, Porto, Portugal), Hospital Joaquim Urbano (HJU, Porto, Portugal) and Centro Hospitalar de Coimbra (CHC, Coimbra, Portugal). A maximum of 30 mL of BAL or BW, and 2 to 4 mL of BS samples were placed in a sterile container and frozen at −70°C for further processing for immunofluorescence staining (IFS) and FC analysis.
Sample preparation
For IFS, clinical samples were mixed with mucolytic agent N-acetyl-L-cysteine (Merck®) and incubated in a water bath at 37°C for 20 min or until complete dissolution, followed by centrifugation at 3,000g for 15 min. Subsequently, the samples were washed twice with sterile water (H 2 O), centrifuged as above and the sediment re-suspended in a small volume of water which was divided into two portions; one portion was placed on a glass slide, air dried and fixed, while the other portion was used for FC analysis.
Immunofluorescence staining Smears were stained according to the manufacturer's instructions with the Detect IF™ kit Pneumocystis carinii (Axis-Shield Diagnostics Limited, United Kingdom) and analysed under an epifluorescence microscope Leitz Laborlux K (Leica, NY, USA). Smears were considered to be positive for P. jirovecii whenever two or more green cysts were visualised, whether isolated or in a group.
Optimisation of a flow cytometry protocol
For the optimisation of the FC protocol, a mix of four positive samples and a mix of four negative samples (evaluated by IFS) were prepared. Samples were divided into two equal aliquots and one of them was passed through a filter with a 30-μm pore size (Partec CellTrics®). Twenty microlitres of specific enzyme from Detect IF™ kit Pneumocystis carinii (Axis-Shield Diagnostics Limited, United Kingdom) were added to 100 µl of the respiratory sample and incubated at 37°C for 30 min; 500 µl of sterile H 2 O were then added and a subsequent centrifugation was performed at 3,000g for 5 min.
One hundred microlitres of centrifuged sample were stained with serial concentrations (0, 5.0, 10.0, 15.0 and 20.0 μl) of specific P. jirovecii mouse monoclonal antibody (Axis-Shield Diagnostics Limited, United Kingdom), followed by dark incubation at 37°C for 15 min. Subsequently, 500 µl of sterile H 2 O were added and centrifugation at 3,000g for 5 min was performed; the supernatant was discarded and the pellet re-suspended in 100 μl of sterile H 2 FL1] ). Acquisition settings were defined using a non-stained sample (autofluorescence) and adjusting the PMTs' voltage to the first logarithmic (log) decade. Instrument controls followed the described standard procedures indicated by the manufacturer.
Assessment of the sensitivity and specificity of the flow cytometry staining protocol
To assess the specificity, positive and negative IFS samples for P. jirovecii were mixed with 1×10 6 cells/ml of different microorganisms, namely, Escherichia coli type strain ATCC 35218 from the American Type Culture Collection (ATCC), Staphylococcus aureus ATCC 25923 and Candida albicans ATCC 10231. The mix was stained with the specific P. jirovecii antibody under optimised conditions and analysed by FC.
Evaluation of clinical respiratory samples
All clinical samples were analysed by both IFS and by FC according to the previously optimised conditions and the results were subsequently compared.
Data comparison
The results of IFS were compared to those obtained by FC. Clinical diagnosis was used as the standard. When results were discrepant, clinical symptoms and signs were considered; patients with oxygen level PaO 2 <70 mmHg, an X-ray depicting a diffuse bilateral infiltrate and with a favourable outcome upon specific therapy were considered as truepositive cases for PcP.
Results
Respiratory samples were considered to be positive for P. jirovecii when two or more green round formations, namely, cysts, were observed on epifluorescence microscopy. By IFS, 340 samples were negative and 80 samples were positive for P. jirovecii.
Since there is not an available commercial type strain of P. jirovecii, we used a mix of four IFS-positive and four IFS-negative samples (without cysts) as material for the optimisation of the FC protocol. As we increased the specific antibody concentrations, an increase of the mean intensity of fluorescence (MIF) was also clear. Twenty microlitres of specific antibody resulted in the highest value of MIF at FL1, although a similar staining pattern was obtained with 10.0 or 15.0 µl (Fig. 1) . As such, all further experiments were carried out with the lowest concentration sufficient to detect the organisms from the autofluorescence background, i.e. 10.0 µl.
To determine the specificity of the staining, microorganisms usually present in respiratory samples were mixed with negative and positive control samples, which were then incubated with the monoclonal antibody. Although an increase in events was detectable in the presence of high concentrations of bacteria, those events were not selected in our settings due to their smaller size; yeasts Region R corresponds to the acquisition gate of P. jirovecii cysts stained with specific antibody appeared near the acquisition gate corresponding to P. jirovecii cysts but displayed much lower fluorescence intensity than that of the stained cysts (Fig. 2) .
Upon optimisation of the cytometric protocol, clinical samples were analysed. Sample preparation included mucolytic agent, with and without filtration (30-µm pore size). A greater number of non-fluorescent cytometric events occurred on samples without filtration, leading to difficulties in its interpretation. A better separation of stained cysts from debris was obtained upon filtration without signal lost (Fig. 3) . For FC analysis, we considered positive all the respiratory samples whose events appeared on the acquisition gate R corresponding to P. jirovecii cysts stained with specific antibody (typical example shown in Fig. 3 ). Through FC, we found 88 positive samples, 35 of which belonged to HIV patients (27%). Eighty positive cases (19%) were detected by both IFS and FC methods. However, eight clinical samples previously considered to be negative by IFS were found to be positive by FC assay (Table 1 ). All eight cases were from HIV-positive patients with clinical diagnostic criteria of PcP such as fever, cough, shortness of breath, weight loss associated with pulmonary infiltrates on chest X-ray and an arterial oxygen low level. In addition, the patients had improved upon specific treatment with trimethoprim, despite negative IFS. Considering the clinical criteria as the diagnostic standard, such cases should be considered as truepositives. According to our study, FC analysis displays 100% sensitivity and specificity versus 90.9% sensitivity and 100% specificity for the IFS assay. Consequently, IFS presented a positive predictive value of 100% and a negative predictive value of 97.6%.
Discussion
Specific and prompt diagnosis of P. jirovecii infection has significant clinical relevance, since this opportunistic organism can cause severe pneumonia in immunocompromised patients [6] . As this organism cannot be cultured in vitro, the standard diagnostic procedure for the detection of P. jirovecii relies upon the direct microscopic examination of the clinical specimen. Using commercialised fluorescein or enzyme-labelled monoclonal or polyclonal Pneumocystis antibodies in respiratory samples, a higher detection sensitivity can be achieved [11] . Considering the increasing complexity of diagnostic laboratory techniques, resulting in higher costs and the need for greater human expertise, the development of more sensitive and automated methods which allow a rapid assessment of clinical specimens is highly recommended. FC is a method based upon the evaluation of cell fluorescence, which has frequently shown to be specific and yielding great sensitivity. Moreover, it allows the detection of low threshold limits, which are difficult to obtain by standard methods [16] [17] [18] [19] . The first cytometric study regarding the formerly P. carinii was developed by Libertin et al. [19] in lung homogenates samples from infected mice and humans, however, without practical application. Later assays were performed by Lapinsky et al. [20] in order to observe the pharmacological action of drugs upon the growth and viability of these microorganisms in animal models. The flow cytometer is an expensive piece of equipment present in most immunology laboratories that could probably be easily shared by microbiologists. Since the amount of specific monoclonal antibody is lower than that used for IFS, it has the potential to be more economic.
Our study aimed to develop and optimise the cytometric analytical protocol regarding clinical samples. An important condition should be fulfilled: the concentration of the probe should be at its minimum to allow a clear separation of the stained population from all other events; while insufficient staining would not allow a clear separation from debris, excessive staining could result in unspecific fluorescence. Our study faced a number of limitations such as the absence of a commercially available type strain, as well as the relatively low number of positive samples, often containing very few organisms, which made it difficult to assess the sensitivity limit. Cytometric analysis could be difficult to perform in the presence of organic debris and, as such, the filtration step prior to specific antibody staining resulted in an improved discrimination of debris from P. jirovecii organisms. In order to confirm the specificity of the monoclonal antibody used in this study, cross-reactions were investigated using both prokaryotic (E. coli, S. aureus) and eukaryotic microorganisms (C. albicans) mixed in a negative sample for P. jirovecii. An increased number of events was clear, although without staining with the specific antibody (only fungi showed a very slight increase in green fluorescence), demonstrating that the test is quite specific.
The results from the 420 clinical samples collected from putative PcP patients revealed that, in accordance to the literature reports, only 19% of the samples were positive by both methods (IFS and CF), possibly due to the extensive use of prophylaxis among the risk population [21, 22] . However, regarding the HIV-positive population, the percentage which we found is in agreement with the literature [21] . Comparing the results from FC to those of IFS, several cases would have to be considered as falsepositives. However, taking into account medical criteria as the final diagnosis, those should be considered as truepositives.
Thus, a new cytometric detection method is now available for a more reliable detection of P. jirovecii organisms in respiratory clinical samples. 
